Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 159

1.

Plasma long pentraxin 3 (PTX3) concentration is a novel marker of disease activity in patients with community-acquired pneumonia.

Kao SJ, Yang HW, Tsao SM, Cheng CW, Bien MY, Yu MC, Bai KJ, Yang SF, Chien MH.

Clin Chem Lab Med. 2013 Apr;51(4):907-13. doi: 10.1515/cclm-2012-0459.

PMID:
23152412
2.

Plasma endothelial cell-specific molecule-1 (ESM-1) in management of community-acquired pneumonia.

Kao SJ, Chuang CY, Tang CH, Lin CH, Bien MY, Yu MC, Bai KJ, Yang SF, Chien MH.

Clin Chem Lab Med. 2014 Mar;52(3):445-51. doi: 10.1515/cclm-2013-0638.

PMID:
24108208
3.

Circulating level of lipocalin 2 as a predictor of severity in patients with community-acquired pneumonia.

Yeh YH, Chang JL, Hsiao PC, Tsao SM, Lin CH, Kao SJ, Chou MC, Yang SF, Chien MH.

J Clin Lab Anal. 2013 Jul;27(4):253-60. doi: 10.1002/jcla.21588.

PMID:
23852780
4.

Utility of Plasma Osteopontin Levels in Management of Community-Acquired Pneumonia.

Chang JH, Hung WY, Bai KJ, Yang SF, Chien MH.

Int J Med Sci. 2016 Aug 10;13(9):673-9. doi: 10.7150/ijms.16175. eCollection 2016.

5.

Plasma Monocyte Chemoattractant Protein-1 Level as a Predictor of the Severity of Community-Acquired Pneumonia.

Yong KK, Chang JH, Chien MH, Tsao SM, Yu MC, Bai KJ, Tsao TC, Yang SF.

Int J Mol Sci. 2016 Jan 29;17(2). pii: E179. doi: 10.3390/ijms17020179.

6.

Significant elevation of plasma cathepsin B and cystatin C in patients with community-acquired pneumonia.

Lee YT, Chen SC, Shyu LY, Lee MC, Wu TC, Tsao SM, Yang SF.

Clin Chim Acta. 2012 Mar 22;413(5-6):630-5. doi: 10.1016/j.cca.2011.12.010. Epub 2011 Dec 20.

PMID:
22209964
7.

Plasma levels of soluble intercellular adhesion molecule-1 as a biomarker for disease severity of patients with community-acquired pneumonia.

Chang PY, Tsao SM, Chang JH, Chien MH, Hung WY, Huang YW, Yang SF.

Clin Chim Acta. 2016 Dec 1;463:174-180. doi: 10.1016/j.cca.2016.10.030. Epub 2016 Oct 28.

PMID:
27983998
8.

Plasma levels of soluble Axl correlate with severity of community-acquired pneumonia.

Ko CP, Yu YL, Hsiao PC, Yang SF, Yeh CB.

Mol Med Rep. 2014 Apr;9(4):1400-4. doi: 10.3892/mmr.2014.1933. Epub 2014 Feb 6.

PMID:
24503651
9.

Usefulness of plasma YKL-40 in management of community-acquired pneumonia severity in patients.

Wang HL, Hsiao PC, Tsai HT, Yeh CB, Yang SF.

Int J Mol Sci. 2013 Nov 19;14(11):22817-25. doi: 10.3390/ijms141122817.

10.

[Clinical study of Pentraxin 3 in diagnosing the severity and cardiovascular function of the children with sepsis].

Kang X, Zhu Y, Zhang X.

Zhonghua Er Ke Za Zhi. 2015 Aug;53(8):592-8. Chinese.

PMID:
26717657
11.

Significant elevation of plasma pentraxin 3 in patients with pelvic inflammatory disease.

Chang CC, Wang PH, Su PH, Lin DB, Ying TH, Yang SF, Hsieh YH.

Clin Chem Lab Med. 2011 Oct;49(10):1655-60. doi: 10.1515/CCLM.2011.650. Epub 2011 Jun 17.

PMID:
21679133
12.

Long Pentraxin 3 as a Predictive Marker of Mortality in Severe Septic Patients Who Received Successful Early Goal-Directed Therapy.

Kim SB, Lee KH, Lee JU, Ann HW, Ahn JY, Jeon YD, Kim JH, Ku NS, Han SH, Choi JY, Song YG, Kim JM.

Yonsei Med J. 2017 Mar;58(2):370-379. doi: 10.3349/ymj.2017.58.2.370.

13.

Alveolar pentraxin 3 as an early marker of microbiologically confirmed pneumonia: a threshold-finding prospective observational study.

Mauri T, Coppadoro A, Bombino M, Bellani G, Zambelli V, Fornari C, Berra L, Bittner EA, Schmidt U, Sironi M, Bottazzi B, Brambilla P, Mantovani A, Pesenti A.

Crit Care. 2014 Oct 15;18(5):562. doi: 10.1186/s13054-014-0562-5.

14.

Elevated concentrations of pentraxin 3 are associated with coronary plaque vulnerability.

Soeki T, Niki T, Kusunose K, Bando S, Hirata Y, Tomita N, Yamaguchi K, Koshiba K, Yagi S, Taketani Y, Iwase T, Yamada H, Wakatsuki T, Akaike M, Sata M.

J Cardiol. 2011 Sep;58(2):151-7. doi: 10.1016/j.jjcc.2011.04.005. Epub 2011 Jun 14.

15.

Elevated plasma stromal-cell-derived factor-1 protein levels correlate with severity in patients with community-acquired pneumonia.

Tsai PK, Hsieh MJ, Wang HL, Chou MC, Yang SF, Yeh CB.

Dis Markers. 2014;2014:829706. doi: 10.1155/2014/829706. Epub 2014 Oct 13.

16.

[Evaluation of the mannose-binding lection gene polymorphism on the severity of community acquired pneumonia in adults].

Liu X, Zhang X, Li Q, Tian Z.

Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2014 Sep;26(9):655-60. doi: 10.3760/cma.j.issn.2095-4352.2014.09.010. Chinese.

17.

Long pentraxin 3: a marker of inflammation in untreated psoriatic patients.

Bevelacqua V, Libra M, Mazzarino MC, Gangemi P, Nicotra G, Curatolo S, Massimino D, Plumari A, Merito P, Valente G, Stivala F, La Greca S, Malaponte G.

Int J Mol Med. 2006 Sep;18(3):415-23.

PMID:
16865225
18.

The circulating level of MMP-9 and its ratio to TIMP-1 as a predictor of severity in patients with community-acquired pneumonia.

Chiang TY, Yu YL, Lin CW, Tsao SM, Yang SF, Yeh CB.

Clin Chim Acta. 2013 Sep 23;424:261-6. doi: 10.1016/j.cca.2013.06.013. Epub 2013 Jun 20.

PMID:
23792071
19.

Pentraxin 3 Is Closely Associated With Tubulointerstitial Injury in Lupus Nephritis: A Large Multicenter Cross-Sectional Study.

Pang Y, Tan Y, Li Y, Zhang J, Guo Y, Guo Z, Zhang C, Yu F, Zhao MH.

Medicine (Baltimore). 2016 Jan;95(3):e2520. doi: 10.1097/MD.0000000000002520.

20.

High plasma level of long pentraxin 3 (PTX3) is associated with fatal disease in bacteremic patients: a prospective cohort study.

Huttunen R, Hurme M, Aittoniemi J, Huhtala H, Vuento R, Laine J, Jylhävä J, Syrjänen J.

PLoS One. 2011 Mar 10;6(3):e17653. doi: 10.1371/journal.pone.0017653.

Supplemental Content

Support Center